Helicobacter Pylori Eradication Clinical Trial
Official title:
Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective, Single-center, Open-label, Randomized Controlled Trial
Although Urea breath test has been commonly used to recheck the efficiency of Helicobacter pylori eradication, there has been no randomized trials comparing the accuracy of Urea breath test results at different times after eradication. The investigators aim to assess the accuracy and influence factors of post-therapy test at different times and follow up the cut off samples to optimize the best time to recheck.
Status | Recruiting |
Enrollment | 900 |
Est. completion date | August 21, 2024 |
Est. primary completion date | April 21, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - no history of helicobacter pylori treatment - the diagnosis of H. pylori infection was confirmed by one or more of the following methodologies before treatment: gastric biopsy using histochemical staining, tissue culture, the 14C-urea breath test (UBT), and/or the 13C-UBT. Exclusion Criteria: - used antibiotics or bismuth within four weeks before inclusion or acid inhibitor use, including H2 receptor antagonist (H2RA), PPI or P-CAB use, within two weeks prior to inclusion. - had an active peptic ulcer with complications such as hemorrhage, perforation, or obstruction. - had a history of esophagectomy or gastrectomy. - had an allergy to any study drug. - had severe comorbidities or physical or mental diseases. - were pregnant or breastfeeding. - had a history of alcohol abuse or drug addiction. |
Country | Name | City | State |
---|---|---|---|
China | 2nd Affilicated Hosptal,School of Medicine,Zhejiang University,China | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the eradication rate in each group (ITT analysis) | According to the breath urea test, calculation the eradication rate in the three groups. ITT analysis, the number of negative breath test cases after treatment divided by the number of cases enrolled in eradication therapy. | up to 4 months after eradication therapy | |
Primary | the eradication rate in each group (PP analysis) | According to the breath urea test, calculation the eradication rate in the three groups. PP analysis, the number of negative breath test cases after treatment divided by the number of cases finished the eradication therapy | up to 4 months after eradication therapy | |
Secondary | follow up of cut off cases | If the result of breath urea test is betwwen 2 to 6, it will be defined as cut off value. These cases will be collected and take further tests to make sure the real situation of helicobacter pylori infection. | up to 4 months after eradication therapy. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02873065 -
Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori
|
Phase 4 | |
Recruiting |
NCT06349486 -
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication
|
N/A | |
Completed |
NCT03924375 -
Serum Pepsinogen After H. Pylori Eradication
|
||
Recruiting |
NCT04034641 -
Effect of Probiotics on Helicobacter Pylori Eradication
|
Phase 4 | |
Completed |
NCT04850209 -
The Impact of WeChat Group Patient Education on the Eradication Rate of Helicobacter Pylori
|
N/A | |
Not yet recruiting |
NCT04558502 -
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
|
Phase 4 | |
Completed |
NCT06101420 -
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
|
Phase 3 | |
Recruiting |
NCT06088316 -
Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT
|
Phase 4 | |
Recruiting |
NCT05850117 -
Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p
|
N/A | |
Recruiting |
NCT05191888 -
14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
|
Phase 4 |